Unichem Laboratories Ltd(UNICHEMLAB)

NSE: UNICHEMLABBSE: 506690

₹ 470-3.72%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 3,309 crNext results: 4 Nov 2026Website: www.unichemlabs.comUpdated: 24 Oct 2026

About

Unichem Laboratories Ltd is an Indian pharmaceutical company focused on formulations and active pharmaceutical ingredients (APIs), with consolidated revenue of Rs 2,201.85 crores in FY26. Exports constitute 98.02% of sales revenue, with the US generics business contributing 64% of total sales as of FY25. The company is part of the Ipca group and operates USFDA-inspected manufacturing facilities in India.^[1][2]

Business segments

Formulations (standalone exports + domestic): revenue of Rs 1,527.63 crores in FY25, the primary segment.^[2]
APIs & Intermediates (standalone): revenue of Rs 161.17 crores in FY25.^[2]

R&D pipeline and filings

Cumulative 84 ANDAs filed (71 approved), 79 USDMFs and 30 CEPs as of FY25; R&D team of over 300 scientists.^[2]
4 ANDA approvals and 4 US product launches in FY25; R&D spend was Rs 90 crores in FY25 vs Rs 104.67 crores in FY24.^[2]

Manufacturing and USFDA status

Two formulation facilities received USFDA Establishment Inspection Reports (EIRs) with Voluntary Action Indicated (VAI) status in FY25.^[2]
Several facilities completed EU-GMP audits and received EU-GMP certifications in FY25.^[2]

Key operating numbers

Formulation output grew 52% from 9.98 billion tablets/capsules in FY24 to 15.17 billion in FY25.^[2]
US generics business grew 22.2% year-on-year in FY25.^[2]
Consolidated revenue grew 18.3% to Rs 2,110.97 crores in FY25; standalone revenue grew 20.4% to Rs 1,735.70 crores.^[2]

Customers and distribution

Exports constitute 98.02% of sales revenue in FY25; the US generics market accounts for 64% of total sales revenue.^[2]

Expansion and capex

Capex of Rs 126.31 crores incurred in FY25; Pithampur plant expansion Phase I completed, enhancing installed capacity by 81%.^[2]
Pithampur plant Phase II expansion was expected to capitalise in the year following FY25.^[2]

Recent developments

On 19 Sep 2026, Unichem received a penalty order of Rs 87,07,09,556 under the CGST Act 2017 and Maharashtra SGST Act 2017 for disallowed tax liability of Rs 6,58,76,590; the company stated it will file an appeal within prescribed timelines.^[3]
Company is part of the Ipca group and expects to benefit from Ipca's capabilities, capacities, distribution network and product portfolio going forward.^[2]

Market Cap

₹3,309 Cr

High / Low

₹686 / 280

Stock P/E

10.9

Price / Book

1.2

Book Value

₹386

EPS

₹35.9

No. of Shares

7.04 Cr

ROCE

4.0%

ROE

9.8%

OPM

5.4%

Debt / Equity

0.17

Sales

₹2,202 Cr

Net Profit

₹253 Cr

Promoter holding

70.2%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials